DelveInsight’s “Exocrine Pancreatic Insufficiency (EPI) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Exocrine Pancreatic Insufficiency (EPI) , historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency (EPI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Exocrine Pancreatic Insufficiency (EPI) market report provides current treatment practices, emerging drugs, Exocrine Pancreatic Insufficiency (EPI) market share of the individual therapies, current and forecasted Exocrine Pancreatic Insufficiency (EPI) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Exocrine Pancreatic Insufficiency (EPI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Exocrine Pancreatic Insufficiency (EPI) is a degenerative disease caused by the insufficient production and secretion of pancreatic digestive enzymes which leads to maldigestion (an inability to breakdown nutrients) in the duodenum. It is commonly caused by a reduction in functioning pancreatic tissue or ductal disease, such as in chronic pancreatitis and pancreatic malignancy. It can also result from reduced enterohormonal stimulation of the pancreas in severe duodenal mucosal disease, and from anatomical changes following gastrointestinal surgery. The condition is associated with significant morbidity and reductions in quality of life, even in milder forms.

 

 

Request for :- free sample page

 

 

 

1.  As per the study conducted by Lin Y Tamakosh et al., titled “Nationwide epidemiological survey of chronic pancreatitis in Japan” the estimated prevalence of EPI in Japan is more than 25 cases per 100,000 with a higher rate in men compared to women.

 

2. According to a study titled “Epidemiology of pancreatic diseases in Luneburg County. A study in a defined German population” conducted by Lankisch PG et al. the estimated prevalence of EPI in defined German population is 6.4 cases per 100,000 inhabitants.

“As per the study conducted by M. Othman et al. (2018), the prevalence of EPI can be quite high among certain sub-groups of individuals such as those with chronic pancreatitis (CP), cystic fibrosis (CF), pancreatic cancer, and pancreas resection. EPI may be particularly common whenever diarrhea is present, whether with IBS (6%) or coeliac disease, despite adopting a gluten-free diet (30%). Further, the prevalence of EPI also appears to increase with age”

 

1. Solvay Pharmaceuticals
2. Janssen Pharmaceuticals
3. Adare Pharma Co.
4. Repha GmbH

 Name of drugs covered that are given below:- 

1. Creon
2. Pancreaze
3. Zenpep
4. Nortase

1. Key Insights

2. Executive Summary of Exocrine Pancreatic Insufficiency (EPI)

3. Competitive Intelligence Analysis for Exocrine Pancreatic Insufficiency (EPI)

4. Exocrine Pancreatic Insufficiency (EPI) : Market Overview at a Glance

4.1. Exocrine Pancreatic Insufficiency (EPI) Total Market Share (%) Distribution in 2017

4.2. Exocrine Pancreatic Insufficiency (EPI) Total Market Share (%) Distribution in 2030

5. Exocrine Pancreatic Insufficiency (EPI) : Disease Background and Overview

6. Patient Journey

7. Exocrine Pancreatic Insufficiency (EPI) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Exocrine Pancreatic Insufficiency (EPI) Treatment and Management

8.2. Exocrine Pancreatic Insufficiency (EPI) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Exocrine Pancreatic Insufficiency (EPI) Treatment

11. Marketed Products

12. Emerging Therapies

13. Exocrine Pancreatic Insufficiency (EPI) : Seven Major Market Analysis

13.1. Key Findings

13.2. Exocrine Pancreatic Insufficiency (EPI) Market Size in 7MM

13.3. Exocrine Pancreatic Insufficiency (EPI) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Exocrine Pancreatic Insufficiency (EPI)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

• The report will help in developing business strategies by understanding trends shaping and driving the Exocrine Pancreatic Insufficiency (EPI) market
• To understand the future market competition in the Exocrine Pancreatic Insufficiency (EPI) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Exocrine Pancreatic Insufficiency (EPI) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Exocrine Pancreatic Insufficiency (EPI) market
• To understand the future market competition in the Exocrine Pancreatic Insufficiency (EPI) market

Related Reports:- 

1. Exocrine Pancreatic Insufficiency (EPI) – Epidemiology Forecast to 2030

2. Exocrine Pancreatic Insufficiency- Market Insight, Epidemiology and Market Forecast -2030